

THE AMERICAN JOURNAL OF MANAGED CARE®

Publishing Staff

Senior Vice President
of Operations and Clinical Affairs
Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager
Ida Delmendo

Clinical Projects Manager
Cindy Spielvogel

Project Director
Christina Doong

Quality Assurance Editor
David Allikas

Associate Editor
Jeanne Linke

Design Director
Charles Lebeda

Associate Publisher
Andrew Colon

Director of Sales
Sara Stewart

National Account Managers
Gabrielle Consola
Michael Costella

Corporate

Chairman and CEO
Mike Hennessy

Vice Chairman
Jack Lepping

President
Tighe Blazier

Chief Financial Officer
Neil Glasser, CPA/CFE

President, Managed Markets
Brian Haug

Executive Vice President
and General Manager

John Maglione

Vice President of Human Resources
Rich Weisman

Vice President, Executive Creative
Director
Jeff Brown

Vice President of Education
David Heckard

Copyright © 2015 by Managed Care
& Healthcare Communications, LLC

April 2015 – Vol. 21, No. 7, Sup.

Emerging Evidence in NSAID Pharmacology: Important Considerations for Product Selection

Table of Contents

Participating Faculty

S138

Report

■ Emerging Evidence in NSAID Pharmacology: Important Considerations for Product Selection

S139

Tracy S. Hunter, PhD, MS, BS Pharm;
Chip Robison, PharmD, RPh;
and Philip P. Gerbino, PharmD, BSc



MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ A518

Emerging Evidence in NSAID Pharmacology: Important Considerations for Product Selection

This supplement was sponsored by **Iroko Pharmaceuticals, LLC**.

...

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Emerging Evidence in NSAID Pharmacology: Important Considerations for Product Selection

This supplement to *The American Journal of Managed Care* looks at emerging evidence in NSAID pharmacology, including the relationship between COX selectivity and NSAID dose, the effect of NSAID dosing on adverse events, and pharmacokinetic principles to consider in selecting an NSAID product.

■ Faculty

Philip P. Gerbino, PharmD, BSc

President Emeritus
University of the Sciences
Linwood F. Tice Professor Emeritus
Philadelphia College of Pharmacy
Philadelphia, Pennsylvania

Tracy S. Hunter, PhD, MS, BS Pharm

Professor and Director of Continuing Professional Development
Wingate University School of Pharmacy
Wingate, North Carolina

Chip Robison, PharmD, RPh

Regional Coverage Pharmacist
Healix Infusion Therapy
Atlanta, Georgia

■ Faculty Disclosures

These faculty report relationships with the following organizations:

Philip P. Gerbino, PharmD, BSc

Advisory board:

ACRO Pharmaceutical Services

Tracy S. Hunter, PhD, MS, BS Pharm, and **Chip Robison, PharmD, RPh**, have no relevant financial relationships with commercial interests to disclose.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

■ SUPPLEMENT POLICY STATEMENT ■

Standards for Supplements to *The American Journal of Managed Care*

All supplements to *The American Journal of Managed Care* are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All *Journal* supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to *The American Journal of Managed Care* will:

- I. Be reviewed by at least one independent expert from a recognized academic medical institution.
- II. Disclose the source of funding in at least one prominent place.
- III. Disclose any existence of financial interests of supplement contributors to the funding organization.
- IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.
- V. Be up-to-date, reflecting the current (as of date of publication) standard of care.
- VI. Be visually distinct from *The American Journal of Managed Care*.
- VII. Publish information that is substantially different in form and content from that of the accompanying edition of *The American Journal of Managed Care*.
- VIII. Prohibit excessive remuneration for contributors and reviewers.
- IX. Carry no advertising.

Publisher's Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of *The American Journal of Managed Care*. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.